Tags

Type your tag names separated by a space and hit enter

Effect of vasodilator therapy on mortality in chronic congestive heart failure.
J Assoc Physicians India. 1993 May; 41(5):269-71.JA

Abstract

We compared the effects of Hydralazine and Isosorbide dinitrate (ISDN) with those of an angiotensin-converting-enzyme inhibitor, captopril on mortality in patients with chronic congestive heart failure (NYHA class III and IV). Patients receiving conventional treatment with digoxin and diuretics were randomly assigned to receive either placebo (n = 51), hydralazine-ISDN. (n = 50) or captopril (n = 52) in a double blind trial. At the end of 6 months there were 14 deaths in the placebo group (27.4%) as compared with 11 deaths in the hydralazine-ISDN group (22%)--a mortality reduction of 20% (P > 0.05) and 10 deaths in the captopril group (19.2%)--a mortality reduction of 30% (p > 0.05). At the end of one year, mortality was 50%, 42% and 30% in the placebo, hydralazine-ISDN and captopril groups respectively with a mortality reduction of 16% in the hydralazine-ISDN group (p > 0.05) and 40% in the captopril group (p < 0.05) compared to the placebo group. The mortality reduction was mainly due to reduction in deaths attributed to progressive heart failure. The data suggests that the addition of captopril to conventional treatment significantly reduces mortality in patients with severe congestive heart failure. Hydralazine-isorobide dinitrate also reduced mortality but statistically this was not significant.

Authors+Show Affiliations

Department of Cardiology, NRS Medical College Hospital, Calcutta.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8300456

Citation

Ghose, J C., et al. "Effect of Vasodilator Therapy On Mortality in Chronic Congestive Heart Failure." The Journal of the Association of Physicians of India, vol. 41, no. 5, 1993, pp. 269-71.
Ghose JC, Chakraborty S, Mondal M, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. J Assoc Physicians India. 1993;41(5):269-71.
Ghose, J. C., Chakraborty, S., Mondal, M., & Bhandari, B. (1993). Effect of vasodilator therapy on mortality in chronic congestive heart failure. The Journal of the Association of Physicians of India, 41(5), 269-71.
Ghose JC, et al. Effect of Vasodilator Therapy On Mortality in Chronic Congestive Heart Failure. J Assoc Physicians India. 1993;41(5):269-71. PubMed PMID: 8300456.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of vasodilator therapy on mortality in chronic congestive heart failure. AU - Ghose,J C, AU - Chakraborty,S, AU - Mondal,M, AU - Bhandari,B, PY - 1993/5/1/pubmed PY - 1993/5/1/medline PY - 1993/5/1/entrez SP - 269 EP - 71 JF - The Journal of the Association of Physicians of India JO - J Assoc Physicians India VL - 41 IS - 5 N2 - We compared the effects of Hydralazine and Isosorbide dinitrate (ISDN) with those of an angiotensin-converting-enzyme inhibitor, captopril on mortality in patients with chronic congestive heart failure (NYHA class III and IV). Patients receiving conventional treatment with digoxin and diuretics were randomly assigned to receive either placebo (n = 51), hydralazine-ISDN. (n = 50) or captopril (n = 52) in a double blind trial. At the end of 6 months there were 14 deaths in the placebo group (27.4%) as compared with 11 deaths in the hydralazine-ISDN group (22%)--a mortality reduction of 20% (P > 0.05) and 10 deaths in the captopril group (19.2%)--a mortality reduction of 30% (p > 0.05). At the end of one year, mortality was 50%, 42% and 30% in the placebo, hydralazine-ISDN and captopril groups respectively with a mortality reduction of 16% in the hydralazine-ISDN group (p > 0.05) and 40% in the captopril group (p < 0.05) compared to the placebo group. The mortality reduction was mainly due to reduction in deaths attributed to progressive heart failure. The data suggests that the addition of captopril to conventional treatment significantly reduces mortality in patients with severe congestive heart failure. Hydralazine-isorobide dinitrate also reduced mortality but statistically this was not significant. SN - 0004-5772 UR - https://www.unboundmedicine.com/medline/citation/8300456/Effect_of_vasodilator_therapy_on_mortality_in_chronic_congestive_heart_failure_ L2 - https://medlineplus.gov/heartfailure.html DB - PRIME DP - Unbound Medicine ER -